← Back to Clinical Trials
Recruiting NCT07732556

NCT07732556 Midpoint Transverse Process to Pleura (MTP) Block vs Erector Spinae Plane (ESP) Block for Acute Herpes Zoster (HZ) Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07732556
Status Recruiting
Phase
Sponsor Tanta University
Condition Midpoint Transverse Process to Pleura Block
Study Type INTERVENTIONAL
Enrollment 90 participants
Start Date 2026-07-01
Primary Completion 2027-06-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Midpoint transverse process to pleura blockErector spinae plane block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 90 participants in total. It began in 2026-07-01 with a primary completion date of 2027-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to compare the analgesic efficacy and safety of ultrasound-guided midpoint transverse process block versus ultrasound-guided erector spinae plane block in patients suffering from thoracic herpes zoster pain.

Eligibility Criteria

Inclusion Criteria: * Age 21-60 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I-II. * Acute thoracic herpes zoster within 30 days of rash onset. * Moderate to severe pain \[numeric rating scale (NRS)≥4\]. Exclusion Criteria: * Refusal to participate. * Coagulopathy or anticoagulant therapy. * Infection at puncture site. * Allergy to study drugs. * Severe psychiatric illness or inability to assess pain. * Previous thoracic surgery deformity. * Uncontrolled Diabetic patient. * Chronic diseases as renal, hepatic, malignancy. * Patients with chronic disease need analgesia. * Patients are coming for more than 3 months (after healing of rash).

Contact & Investigator

Central Contact

Mohamed A Kazamel, MBBCH

✉ mohamed198330_pg@med.tanta.edu.eg

📞 00201205997183

Frequently Asked Questions

Who can join the NCT07732556 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 60 Years, studying Midpoint Transverse Process to Pleura Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07732556 currently recruiting?

Yes, NCT07732556 is actively recruiting participants. Contact the research team at mohamed198330_pg@med.tanta.edu.eg for enrollment information.

Where is the NCT07732556 trial being conducted?

This trial is being conducted at Tanta, Egypt.

Who is sponsoring the NCT07732556 clinical trial?

NCT07732556 is sponsored by Tanta University. The trial plans to enroll 90 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology